Processa Pharma: Phase 1b interim data show NGC-Cap improved safety with 10x higher 5-FU exposure than capecitabine

Processa Pharmaceuticals, Inc.

NGC-Cap doses: 75-225 mg twice daily vs capecitabine's 1600-2500 mg twice daily; 5-FU exposure up to 10x greater.
Anabolite side effect profile similar to capecitabine; FBAL-related side effects (hand-foot syndrome) almost absent; FBAL exposure ~1% of capecitabine.
FDA acknowledges NGC-Cap as a New Chemical Entity based on altered metabolism and distribution of 5-FU.
Fireside chat scheduled Dec 20 at 4:30 PM ET to discuss data and corporate strategy; results require further studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.